Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 239

1.

Assessing the Diagnostic Yield of Targeted Next-Generation Sequencing for Melanoma and Gastrointestinal Tumors.

Garg S, Gernier S, Misyura M, Sukhai MA, Thomas M, Kamel-Reid S, Stockley T.

J Mol Diagn. 2020 Feb 6. pii: S1525-1578(20)30014-3. doi: 10.1016/j.jmoldx.2019.12.008. [Epub ahead of print]

PMID:
32036084
2.

A 4-gene signature from histologically normal surgical margins predicts local recurrence in patients with oral carcinoma: clinical validation.

Reis PP, Tokar T, Goswami RS, Xuan Y, Sukhai M, Seneda AL, Móz LES, Perez-Ordonez B, Simpson C, Goldstein D, Brown D, Gilbert R, Gullane P, Irish J, Jurisica I, Kamel-Reid S.

Sci Rep. 2020 Feb 3;10(1):1713. doi: 10.1038/s41598-020-58688-y.

3.

Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86).

Dhani NC, Hirte HW, Wang L, Burnier JV, Jain A, Butler MO, Welch S, Fleming GF, Hurteau J, Matsuo K, Matei D, Jimenez W, Johnston C, Cristea M, Tonkin K, Ghatage P, Lheureux S, Mehta A, Quintos J, Tan Q, Kamel-Reid S, Ludkovski O, Tsao MS, Wright JJ, Oza AM.

Clin Cancer Res. 2020 Jan 28. pii: clincanres.2576.2019. doi: 10.1158/1078-0432.CCR-19-2576. [Epub ahead of print]

PMID:
31992589
4.

Latency and interval therapy affect the evolution in metastatic colorectal cancer.

Nikbakht H, Jessa S, Sukhai MA, Arseneault M, Zhang T, Letourneau L, Thomas M, Bourgey M, Roehrl MHA, Eveleigh R, Chen EX, Krzyzanowska M, Moore MJ, Giesler A, Yu C, Bedard PL, Kamel-Reid S, Majewski J, Siu LL, Riazalhosseini Y, Graham DM.

Sci Rep. 2020 Jan 17;10(1):581. doi: 10.1038/s41598-020-57476-y.

5.

The Somatic Curation and Interpretation Across Laboratories (SOCIAL) project-current state of solid-tumour variant interpretation for molecular pathology in Canada.

Spence T, Sukhai MA, Kamel-Reid S, Stockley TL.

Curr Oncol. 2019 Dec;26(6):353-360. doi: 10.3747/co.26.5281. Epub 2019 Dec 1.

6.

Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia.

Puckrin R, Atenafu EG, Claudio JO, Chan S, Gupta V, Maze D, McNamara C, Murphy T, Shuh AC, Yee K, Sibai H, Minden MD, Wei C, Stockley T, Kamel-Reid S, Schimmer AD.

Haematologica. 2020 Jan 2. pii: haematol.2019.235721. doi: 10.3324/haematol.2019.235721. [Epub ahead of print]

7.

The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia.

Hillis CM, Jackson Chornenki NL, Bence-Bruckler I, Busque L, Cote Y, Hamm C, Hasegawa W, Kamel-Reid S, Savoie L, Turner AR, Xenocostas A, Lipton JH, Leber B.

Leuk Res. 2020 Jan;88:106285. doi: 10.1016/j.leukres.2019.106285. Epub 2019 Dec 5. No abstract available.

PMID:
31846781
8.

OCTANE (Ontario-wide Cancer Targeted Nucleic Acid Evaluation): a platform for intraprovincial, national, and international clinical data-sharing.

Malone ER, Saleh RR, Yu C, Ahmed L, Pugh T, Torchia J, Bartlett J, Virtanen C, Hotte SJ, Hilton J, Welch S, Robinson A, McCready E, Lo B, Sadikovic B, Feilotter H, Hanna TP, Kamel-Reid S, Stockley TL, Siu LL, Bedard PL.

Curr Oncol. 2019 Oct;26(5):e618-e623. doi: 10.3747/co.26.5235. Epub 2019 Oct 1.

9.

Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML.

Murphy T, Zou J, Daher-Reyes GS, Arruda A, Gupta V, McNamara CJ, Minden MD, Schimmer AD, Sibai H, Yee KWL, Korulla M, Stockley T, Kamel-Reid S, Maze D, Tierens A, Bratman SV, Schuh AC, Chan SM.

Blood Adv. 2019 Aug 13;3(15):2307-2311. doi: 10.1182/bloodadvances.2019000306. No abstract available.

10.

HPV-independent Vulvar Squamous Cell Carcinoma is Associated With Significantly Worse Prognosis Compared With HPV-associated Tumors.

Allo G, Yap ML, Cuartero J, Milosevic M, Ferguson S, Mackay H, Kamel-Reid S, Weinreb I, Ghazarian D, Pintilie M, Clarke BA.

Int J Gynecol Pathol. 2019 Jul 3. doi: 10.1097/PGP.0000000000000620. [Epub ahead of print]

PMID:
31274700
11.

Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the BRAF, EGFR, and KRAS Genes: A Study of the College of American Pathologists Molecular Oncology Committee.

Moncur JT, Bartley AN, Bridge JA, Kamel-Reid S, Lazar AJ, Lindeman NI, Long TA, Merker JD, Rai AJ, Rimm DL, Rothberg PG, Vasalos P, Kim AS.

Arch Pathol Lab Med. 2019 Oct;143(10):1203-1211. doi: 10.5858/arpa.2018-0396-CP. Epub 2019 Apr 10.

PMID:
30969158
12.

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.

Rodriguez-Freixinos V, Lheureux S, Mandilaras V, Clarke B, Dhani NC, Mackay H, Butler MO, Wang L, Siu LL, Kamel-Reid S, Stockley T, Bedard PL, Oza AM.

Gynecol Oncol. 2019 May;153(2):304-311. doi: 10.1016/j.ygyno.2019.02.005. Epub 2019 Feb 18.

PMID:
30792002
13.

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.

Tomasini P, Mascaux C, Jao K, Labbe C, Kamel-Reid S, Stockley T, Hwang DM, Leighl NB, Liu G, Bradbury PA, Pintilie M, Tsao MS, Shepherd FA.

Clin Lung Cancer. 2019 May;20(3):e338-e345. doi: 10.1016/j.cllc.2018.12.009. Epub 2018 Dec 19.

PMID:
30770327
14.

Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels.

Sukhai MA, Misyura M, Thomas M, Garg S, Zhang T, Stickle N, Virtanen C, Bedard PL, Siu LL, Smets T, Thijs G, Van Vooren S, Kamel-Reid S, Stockley TL.

J Mol Diagn. 2019 Mar;21(2):261-273. doi: 10.1016/j.jmoldx.2018.09.008. Epub 2018 Dec 19.

15.

Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation.

McCarthy AJ, Capo-Chichi JM, Spence T, Grenier S, Stockley T, Kamel-Reid S, Serra S, Sabatini P, Chetty R.

J Pathol Clin Res. 2019 Apr;5(2):115-129. doi: 10.1002/cjp2.120. Epub 2018 Dec 19.

16.

Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays.

Merker JD, Devereaux K, Iafrate AJ, Kamel-Reid S, Kim AS, Moncur JT, Montgomery SB, Nagarajan R, Portier BP, Routbort MJ, Smail C, Surrey LF, Vasalos P, Lazar AJ, Lindeman NI.

Arch Pathol Lab Med. 2019 Apr;143(4):463-471. doi: 10.5858/arpa.2018-0336-CP. Epub 2018 Oct 30.

17.

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.

McNamara CJ, Panzarella T, Kennedy JA, Arruda A, Claudio JO, Daher-Reyes G, Ho J, Siddiq N, Devlin R, Tsui H, Su J, Stockley T, Sukhai M, Kanwar N, Chan S, Maze D, Schimmer A, Schuh A, Sibai H, Viswabandya A, Yee K, Minden MD, Kamel-Reid S, Gupta V.

Blood Adv. 2018 Oct 23;2(20):2658-2671. doi: 10.1182/bloodadvances.2018021469.

18.

Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms.

Kennedy JA, Medeiros JJF, Dobson SM, Arruda A, Sukhai MA, Stockley T, Tierens A, Minden MD, Kamel-Reid S, Dick JE, Gupta V.

Blood. 2018 Nov 15;132(20):2201-2205. doi: 10.1182/blood-2018-04-845065. Epub 2018 Sep 24. No abstract available.

PMID:
30249785
19.

Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy.

Berlin A, Murgic J, Hosni A, Pintilie M, Salcedo A, Fraser M, Kamel-Reid S, Zhang J, Wang Q, Ch'ng C, Deheshi S, Davicioni E, van der Kwast T, Boutros PC, Bristow RG, Chua MLK.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):84-91. doi: 10.1016/j.ijrobp.2018.08.030. Epub 2018 Aug 29.

20.

Additional germline findings from a tumor profiling program.

Stjepanovic N, Stockley TL, Bedard PL, McCuaig JM, Aronson M, Holter S, Semotiuk K, Leighl NB, Jang R, Krzyzanowska MK, Oza AM, Gupta A, Elser C, Ahmed L, Wang L, Kamel-Reid S, Siu LL, Kim RH.

BMC Med Genomics. 2018 Aug 9;11(1):65. doi: 10.1186/s12920-018-0383-5.

Supplemental Content

Loading ...
Support Center